Tempus AI's growth is fueled by data services and acquisitions, despite financial risks. Key Q2 results may shape its path to ...

Tempus AI's growth in precision oncology drives an 80% revenue boost by 2025. Click here to find out why I rate TEM stock a ...

Deep 6’s platform strengthens Tempus AI’s provider connectivity, now totaling over 4,000 connections, and facilitates the two-way exchange of clinical and molecular data.

Tempus AI is a growth stock that is down 31% from all-time highs. Here's why TEM AI stock could be a part of your TFSA portfolio right now.

The integration of artificial intelligence (AI) in the cardiovascular space, particularly in electrocardiography (ECG), is reshaping clinical workflows, enabling earlier disease detection and opening ...

The company's stock jumped 15% as of market close. The spike comes as the S&P 500 (SNPINDEX: ^GSPC) and the Nasdaq Composite (NASDAQINDEX: ^IXIC) jumped 0.4% and 0.6%, respectively. Tempus, a ...

Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, has announced the launch of Notetaker, an AI-powered clinical ...

Tempus AI posted Q1 revenue of $255.74M and a smaller-than-expected loss, signaling strong momentum in precision medicine. Analyst highlights $1B+ in total contract value and 25% topline growth ...

Shares of Tempus AI (NASDAQ: TEM) soared on Monday. The company's stock jumped 15% as of market close. The spike comes as the S&P 500 (SNPINDEX: ^GSPC) and the Nasdaq Composite (NASDAQINDEX: ^IXIC ...

June 02, 2025 — 05:22 pm EDT Written by Johnny Rice for The Motley Fool -> Shares of Tempus AI (NASDAQ: TEM) soared on Monday. The company's stock jumped 15% as of market close.